Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) Income towards Parent Company (2024 - 2025)

Historic Income towards Parent Company for Kura Oncology (KURA) over the last 2 years, with Q3 2025 value amounting to -$74.1 million.

  • Kura Oncology's Income towards Parent Company fell 3623.26% to -$74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$214.9 million, marking a year-over-year change of. This contributed to the annual value of -$174.0 million for FY2024, which is 1398.93% down from last year.
  • Kura Oncology's Income towards Parent Company amounted to -$74.1 million in Q3 2025, which was down 3623.26% from -$66.1 million recorded in Q2 2025.
  • In the past 5 years, Kura Oncology's Income towards Parent Company registered a high of -$17.2 million during Q4 2024, and its lowest value of -$74.1 million during Q3 2025.